Molina Healthcare (MOH) Q2 2025 Earnings Call July 24, 2025 08:00 AM ET Company ParticipantsJeffrey Geyer - VP - IRJoseph Zubretsky - President & CEOMark Keim - CFO & TreasurerAndrew Mok - DirectorJoshua Raskin - Partner - Managed Care & ProvidersA.J. Rice - Managing DirectorJohn Stansel - VP - Equity ResearchConference Call ParticipantsStephen Baxter - Senior Equity Research AnalystJustin Lake - Analyst - Healthcare ServicesKevin Fischbeck - Equity AnalystRyan Langston - Director & Senior Analyst - Healthc ...

Molina Healthcare (MOH) Q2 2025 Earnings Call July 24, 2025 08:00 AM ET Speaker0Good day, and welcome to the Molina Healthcare Second Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Jeff Guyer, Vice President of Investor Relations.Please go ahead.Speaker1Good morning and welcome to Molina Health ...

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose adverse facts regarding its business operations and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Financial Performance - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, which led to a stock price drop of $32.21, or 5.8%, closing at $520.93 per share [2]. - On October 17, 2024, Elevance reported third quarter 2024 financial results, missing EPS consensus estimates by 13.7% and lowering its EPS guidance for 2024 by 11.3%, resulting in a further stock price decline of $52.61, or 10.6%, to close at $444.35 per share [3]. Lawsuit Details - The class action complaint alleges that Elevance's management made materially false and misleading statements and failed to disclose significant adverse facts, including the higher costs associated with sicker patients remaining on Medicaid and inadequate reflection of these costs in financial guidance [4]. - Investors who purchased Elevance common stock during the Class Period have until July 11, 2025, to file a lead plaintiff motion in the lawsuit [5].